Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 5/20 | 0.60 |
| ▸ | PLG | P00747 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067019 | 1.00 | PLAU (0.60) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL28247458 | 0.84 | PLAU (0.62) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL221369 | 0.82 | PLAU (0.60) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL29424817 | 0.81 | PLAU (0.59) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL22547752 | 0.81 | PLAU (0.59) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL15612752 | 0.81 | PLAU (0.59) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL22533790 | 0.81 | PLAU (0.59) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL3891994 | 0.80 | PLAU (0.60) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL15612769 | 0.78 | PLAU (0.55) | PLAUPLGHDAC8HDAC6HDAC11 | |
| SCHEMBL12472875 | 0.78 | PLAU (0.74) | PLAUPLGHDAC8HDAC6HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | ENPP1, ENPP3, SMPD1 | PLAU 2142/4885PLG 1766/4885HDAC8 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.